thalidomide has been researched along with Cancer of Ovary in 21 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To detail the dyspnea encountered in women receiving thalidomide as therapy for advanced ovarian cancer." | 8.82 | Dyspnea during thalidomide treatment for advanced ovarian cancer. ( Dizon, DS; Gordinier, ME, 2005) |
| "Thalidomide was well tolerated: Two patients developed WHO Grade 2 peripheral neuropathy and eight patients developed WHO grade 2 lethargy." | 6.69 | Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. ( Ahern, R; Boshoff, C; Eisen, T; Gore, ME; Johnston, SR; Mak, I; Pyle, L; Sapunar, F; Smith, IE; Vaughan, MM, 2000) |
| "To detail the dyspnea encountered in women receiving thalidomide as therapy for advanced ovarian cancer." | 4.82 | Dyspnea during thalidomide treatment for advanced ovarian cancer. ( Dizon, DS; Gordinier, ME, 2005) |
| "Lenalidomide has dual antiangiogenic and immunomodulatory properties and confirmed antitumor activity in hematologic malignancies." | 2.79 | A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma. ( Berton-Rigaud, D; Fabbro, M; Favier, L; Lesoin, A; Lortholary, A; Mari, V; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Sevin, E, 2014) |
| "Lenalidomide is an anti-angiogenic IMiD(®) immunomodulatory drug." | 2.76 | A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma. ( Carter, JS; Downs, LS, 2011) |
| "Forty patients with Stage IC-IV ovarian cancer were randomly assigned to receive either carboplatin (AUC 7) intravenously every four weeks for up to six doses (n = 20) or carboplatin at the same dose and schedule, plus thalidomide 100 mg orally daily for six months (n = 20)." | 2.76 | A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. ( Blann, AD; Braybrooke, JP; Ganesan, TS; Han, C; Jenkins, A; Kaur, K; Madhusudan, S; Muthuramalingam, SR; Perren, T; Wilner, S, 2011) |
| "Thalidomide was not more effective than tamoxifen in delaying recurrence or death but was more toxic." | 2.75 | Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation ( Benbrook, DM; Brady, MF; Darcy, KM; Edmonds, P; Hurteau, JA; Ivanov, I; Mannel, RS; McGuire, WP; Pearl, ML; Tewari, KS; Zanotti, K, 2010) |
| " The majority of adverse events were grades 1-2, including fatigue (25/80 cycles), nausea/vomiting (23/80), constipation (13/80), abdominal pain (17/80), rash (12/80), neutropenia (12/80), and anemia (12/80)." | 2.73 | Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma. ( Chan, JK; Guo, HY; Husain, A; Teng, NN; Zhang, MM, 2007) |
| "Thalidomide is an antiangiogenic agent with immune modulating potential." | 2.73 | A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. ( Abu-Ghazaleh, SZ; Argenta, PA; Bliss, RL; Boente, MP; Carson, LF; Chen, MD; Downs, LS; Geller, MA; Ghebre, R; Judson, PL; Nahhas, WA, 2008) |
| "Thalidomide is an anti-angiogenesis agent that has shown activity in some solid tumors." | 2.72 | Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. ( Chan, JK; Cheung, MK; Ciaravino, G; Husain, A; Manuel, MR; Teng, NN, 2006) |
| "Thalidomide was well tolerated: Two patients developed WHO Grade 2 peripheral neuropathy and eight patients developed WHO grade 2 lethargy." | 2.69 | Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. ( Ahern, R; Boshoff, C; Eisen, T; Gore, ME; Johnston, SR; Mak, I; Pyle, L; Sapunar, F; Smith, IE; Vaughan, MM, 2000) |
| "Epithelial ovarian cancer (EOC) recurrence is common following treatment with cytoreductive surgery and adjuvant chemotherapy." | 1.35 | Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases. ( Leath, CA; Phippen, NT, 2009) |
| "Thalidomide is an oral immunomodulatory agent with antiangiogenic properties and activity in ovarian cancer." | 1.35 | Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer. ( Buttin, BM; Moore, MJ, 2008) |
| "Treatment with thalidomide is a potentially useful antitumor therapy for ovarian cancer." | 1.33 | [Study of thalidomide on the growth and angiogenesis of ovary cancer SKOV3 transplanted subcutaneously in nude mice]. ( Cao, ZY; Li, W; Peng, ZL, 2005) |
| "Thalidomide has been used to treat a variety of diseases ranging from alleviation of autoimmune disorders to prevention of metastasis of cancers." | 1.33 | Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor kappaB activation and subsequently suppressed ovarian cancer dissemination. ( Haruta, S; Inagaki, K; Kanayama, N; Kawaguchi, R; Kitanaka, T; Kobayashi, H; Kondo, T; Kurita, N; Sakamoto, Y; Terao, T; Yagyu, T; Yamada, Y, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (66.67) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noblejas-López, MDM | 1 |
| Nieto-Jimenez, C | 1 |
| Burgos, M | 1 |
| Gómez-Juárez, M | 1 |
| Montero, JC | 1 |
| Esparís-Ogando, A | 1 |
| Pandiella, A | 1 |
| Galán-Moya, EM | 1 |
| Ocaña, A | 1 |
| Selle, F | 1 |
| Sevin, E | 1 |
| Ray-Coquard, I | 1 |
| Mari, V | 1 |
| Berton-Rigaud, D | 1 |
| Favier, L | 1 |
| Fabbro, M | 1 |
| Lesoin, A | 1 |
| Lortholary, A | 1 |
| Pujade-Lauraine, E | 1 |
| Phippen, NT | 1 |
| Leath, CA | 1 |
| Hurteau, JA | 1 |
| Brady, MF | 1 |
| Darcy, KM | 1 |
| McGuire, WP | 1 |
| Edmonds, P | 1 |
| Pearl, ML | 1 |
| Ivanov, I | 1 |
| Tewari, KS | 1 |
| Mannel, RS | 1 |
| Zanotti, K | 1 |
| Benbrook, DM | 1 |
| Carter, JS | 1 |
| Downs, LS | 2 |
| Muthuramalingam, SR | 1 |
| Braybrooke, JP | 1 |
| Blann, AD | 1 |
| Madhusudan, S | 1 |
| Wilner, S | 1 |
| Jenkins, A | 1 |
| Han, C | 1 |
| Kaur, K | 1 |
| Perren, T | 1 |
| Ganesan, TS | 1 |
| Gordinier, ME | 2 |
| Dizon, DS | 2 |
| Li, W | 1 |
| Peng, ZL | 1 |
| Cao, ZY | 1 |
| Kobayashi, H | 1 |
| Yagyu, T | 1 |
| Kondo, T | 1 |
| Kurita, N | 1 |
| Inagaki, K | 1 |
| Haruta, S | 1 |
| Kawaguchi, R | 1 |
| Kitanaka, T | 1 |
| Sakamoto, Y | 1 |
| Yamada, Y | 1 |
| Kanayama, N | 1 |
| Terao, T | 1 |
| Chan, JK | 2 |
| Manuel, MR | 1 |
| Ciaravino, G | 1 |
| Cheung, MK | 1 |
| Husain, A | 2 |
| Teng, NN | 2 |
| Zhang, MM | 1 |
| Guo, HY | 1 |
| Weitzen, S | 1 |
| Disilvestro, PA | 1 |
| Moore, RG | 1 |
| Granai, CO | 1 |
| Kanwar, VS | 1 |
| Heath, J | 1 |
| Krasner, CN | 1 |
| Pearce, JM | 1 |
| Judson, PL | 1 |
| Argenta, PA | 1 |
| Ghebre, R | 1 |
| Geller, MA | 1 |
| Bliss, RL | 1 |
| Boente, MP | 1 |
| Nahhas, WA | 1 |
| Abu-Ghazaleh, SZ | 1 |
| Chen, MD | 1 |
| Carson, LF | 1 |
| Buttin, BM | 1 |
| Moore, MJ | 1 |
| Braun, AG | 2 |
| Dailey, JP | 1 |
| Eisen, T | 1 |
| Boshoff, C | 1 |
| Mak, I | 1 |
| Sapunar, F | 1 |
| Vaughan, MM | 1 |
| Pyle, L | 1 |
| Johnston, SR | 1 |
| Ahern, R | 1 |
| Smith, IE | 1 |
| Gore, ME | 1 |
| Eisen, TG | 1 |
| Jeyakumar, A | 1 |
| Chalas, E | 1 |
| Hindenburg, A | 1 |
| Abramson, N | 1 |
| Stokes, PK | 1 |
| Luke, M | 1 |
| Marks, AR | 1 |
| Harris, JM | 1 |
| Weinreb, SL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Two Stage Trial of lénalidomide (Revlimid®) : a Phase II Study of lénalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lénalidomide in Combination With Carboplatin and Lipo[NCT01111903] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma[NCT00179712] | Phase 1/Phase 2 | 60 participants | Interventional | 2005-04-30 | Completed | ||
| A Randomized Study Comparing Carboplatin and Thalidomide With Carboplatin Alone in Patients With Stage Ic - IV Ovarian Cancer[NCT00004876] | Phase 2 | 30 participants (Anticipated) | Interventional | 1999-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thalidomide and Cancer of Ovary
| Article | Year |
|---|---|
Dyspnea during thalidomide treatment for advanced ovarian cancer.
Topics: Adult; Aged; Dyspnea; Female; Humans; Immunosuppressive Agents; Middle Aged; Neoplasm Recurrence, Lo | 2005 |
Thalidomide in solid tumors: the London experience.
Topics: Adult; Angiogenesis Inhibitors; Breast Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II a | 2000 |
9 trials available for thalidomide and Cancer of Ovary
| Article | Year |
|---|---|
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epit | 2014 |
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormo | 2010 |
A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug- | 2011 |
A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2011 |
Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; California; Drug Administration Schedule | 2006 |
Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Middle Aged; Neoplasm Recurrence, | 2007 |
A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Midd | 2008 |
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.
Topics: Adult; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Humans; Lymphokines; Male; Me | 2000 |
Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide.
Topics: Adult; Aged; Angiogenesis Inhibitors; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Sero | 2002 |
10 other studies available for thalidomide and Cancer of Ovary
| Article | Year |
|---|---|
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Topics: Animals; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Dipeptides; Drug Resistance, Neoplasm; Fem | 2019 |
Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2009 |
[Study of thalidomide on the growth and angiogenesis of ovary cancer SKOV3 transplanted subcutaneously in nude mice].
Topics: Animals; Cell Proliferation; Cyclophosphamide; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude | 2005 |
Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor kappaB activation and subsequently suppressed ovarian cancer dissemination.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chondrosarcoma; Drug Syne | 2005 |
Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Case-Control Studies; Di | 2007 |
Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Carcinoma, Small | 2008 |
Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer.
Topics: Angiogenesis Inhibitors; Female; Humans; Lung Diseases, Interstitial; Middle Aged; Neoplasm Recurren | 2008 |
Thalidomide metabolite inhibits tumor cell attachment to concanavalin A coated surfaces.
Topics: Animals; Cell Adhesion; Cells, Cultured; Concanavalin A; Female; Mice; Mice, Inbred C3H; Microsomes, | 1981 |
Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Res | 2001 |
Teratogen metabolism: spontaneous decay products of thalidomide and thalidomide analogues are not bioactivated by liver microsomes.
Topics: Animals; Biotransformation; Cell Line; Drug Stability; Female; Hydrogen-Ion Concentration; Hydrolysi | 1985 |